Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential.
PD-L1 inhibitor
bladder cancer
durvalumab
immunotherapy
urothelial carcinoma
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
2
5
2019
pubmed:
2
5
2019
medline:
2
5
2019
Statut:
epublish
Résumé
Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression <12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.
Identifiants
pubmed: 31040693
doi: 10.2147/OTT.S141040
pii: ott-12-2505
pmc: PMC6452813
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2505-2512Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
Cancer. 2006 Aug 1;107(3):506-13
pubmed: 16773629
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
N Engl J Med. 1991 Oct 24;325(17):1205-9
pubmed: 1922207
J Clin Oncol. 2009 Jun 1;27(16):2692-6
pubmed: 19332724
Semin Immunol. 2012 Oct;24(5):331-41
pubmed: 22560929
Interdiscip Top Gerontol. 2013;38:38-48
pubmed: 23503514
PLoS One. 2013 Apr 02;8(4):e60726
pubmed: 23589757
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Front Immunol. 2013 Sep 13;4:271
pubmed: 24062739
Clin Genitourin Cancer. 2014 Apr;12(2):71-3
pubmed: 24355418
Crit Rev Oncog. 2013;18(6):573-83
pubmed: 24579736
Curr Opin Immunol. 2014 Aug;29:105-11
pubmed: 24934647
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Immunol Res. 2015 Sep;3(9):1052-62
pubmed: 25943534
Semin Oncol. 2015 Jun;42(3):474-83
pubmed: 25965366
J Leukoc Biol. 2015 Dec;98(6):937-43
pubmed: 26188078
Lancet. 2016 Apr 9;387(10027):1540-50
pubmed: 26712084
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
J Geriatr Oncol. 2016 Sep;7(5):325-33
pubmed: 27318796
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
An Acad Bras Cienc. 2017 Jan-Mar;89(1):285-299
pubmed: 28423084
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
Eur J Cancer. 2017 Oct;84:212-218
pubmed: 28826074
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Eur J Cancer. 2018 May;95:68-74
pubmed: 29635146
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Clin Exp Immunol. 1987 Sep;69(3):557-65
pubmed: 3499270